Update on diagnosis and prognosis in renal cancer

Poster Session 09

Friday 15 March
10:45 - 12:15

Location: Green Area, Room 12

Chairs: F. D. J. Birkhäuser, Luzern (CH)
S. Dabestani, Malmö (SE)
N. Nonomura, Osaka (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

113

Utility of the modified MAP score for predicting adherent perinephric fat in robot-assisted partial nephrectomy

By: Shiozaki K.¹, Sasaki Y.¹, Nakanishi R.¹, Izaki H.¹, Kanda K.¹, Kawanishi Y.², Yamanaka M.², Izumi K.², Kanayama H.³
¹Tokushima Prefectual Central Hospital, Dept. of Urology, Tokushima, Japan,
²Takamatsu Red Cross Hospital, Dept. of Urology, Tokushima, Japan,
³Tokushima University Hospital, Dept. of Urology, Tokushima, Japan

Aims and objectives of this presentation

114

Association between adherent perinephric fat assessed using MAP score and PnFSD and perioperative outcomes at the time of partial nephrectomy for localized renal mass. A single high-volume referral center experience

By: Di Maida F.¹, Campi R.¹, Tellini R.¹, Sforza S.¹, Cocci A.¹, Corti F.¹, Viola L.¹, Bertelli E.², Lucarini S.², Agostini S.², Siena G.¹, Masieri L.¹, Carini M.¹, Mari A.¹, Minervini A.¹
¹University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy,
²University of Florence, Careggi Hospital, Dept. of Radiology, Florence, Italy

Aims and objectives of this presentation

115

The greatest dimension in 3D sphere has stronger predictive power than 2D plane in the prognosis of renal cell carcinoma

By: Sun Z.¹, Zhao X.¹, Jiang B.¹, Kan Y.¹, Zheng J.², Guo X.², Guo H.¹
¹Affiliated Nanjing Drum Tower Hospital, Nanjing University Medical School, Dept. of Urology, Nanjing, China,
²INCOOL Medical Technology Co. Ltd., Dept. of Technology, Hangzhou, China
Proposal for tripartite reclassification of cT1 renal cell carcinoma into cT1a (very low risk), cT1b (low risk), and cT1c (intermediate risk) substages

By: Bradshaw A. 1, Capitanio U. 2, Uzzo R. 3, Patil D. 4, Eldefrawy A. 1, Larcher A. 2, Joshi S. 3, Ryan S. 1, Margaret M. 1, Cotta B. 1, Yee A. 1, Wan F. 1, Montorsi F. 2, Master V. 4, Derweesh I. 1
1 UC San Diego Health, Dept. of Urology, La Jolla, United States of America, 2 Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 3 Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, 4 Emory University, Dept. of Urology, Atlanta, United States of America

Refining American joint committee on cancer prognostic groups for renal cell carcinoma: A more precise prediction of survival

By: Ning S., Qu Y., Wan F., Ye D.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

The role of non-tumour renal biopsy in patients treated with radical nephrectomy

By: Larcher A. 1, Trevisani F. 1, Dell’Antonio G. 2, Di Marco F. 1, Cinque A. 1, Bettiga A. 1, Muttin F. 1, Porrini E. 3, Doglioni C. 2, Salonia A. 1, Bertini R. 1, Montors F. 1, Capitanio U. 1
1 Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Experimental Oncology, Milan, Italy, 2 IRCCS San Raffaele Scientific Institute, Dept. of Pathology, Milan, Italy, 3 University of La Laguna, Center for Biomedical Research of the Canary Islands (CIBICAN), Tenerife, Spain
Aims and objectives of this presentation
119

* 123

Clinical utility of the mutational landscape and fragment size of circulating tumor DNA in renal cell carcinoma

By: Uemura M. ¹, Yamamoto Y. ¹, Fujita M. ², Maejima K. ², Koh Y. ¹, Matsushita M. ¹, Nakano K. ¹, Hayashi Y. ¹, Wang C. ¹, Ishizuya Y. ¹, Kato T. ¹, Kawashima A. ¹, Ujike T. ¹, Nagahara A. ¹, Fujita K. ¹, Nakagawa H. ², Nonomura N. ¹
¹Osaka University, Graduate School of Medicine, Dept. of Urology, Suita, Japan, ²RIKEN Center for Integrative Medical Sciences, Laboratory for Genome Sequencing Analysis, Tokyo, Japan

Aims and objectives of this presentation
123

124

Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients

By: Xu W.H. ¹, Qu Y-Y. ¹, Jun W. ¹, Wan F.N. ¹, Zhao J.Y. ², Zhang H.L. ¹, Ye D. ¹
¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²The Obstetrics & Gynecology Hospital of Fudan University, State Key Lab of Genetic Engineering, School of Life Sciences and Collaborative Center of Genetics & Development, Fudan University, Shanghai, China

Aims and objectives of this presentation
124

12:04 - 12:08

Summary

S. Dabestani, Malmö (SE)